Table 2.
Distribution of baseline characteristics and outcomes by baseline grade of ischemia
| Characteristic | Baseline grade of ischemia
|
P-value | ||
|---|---|---|---|---|
| Mild | Moderate | Severe | ||
| N | 13 | 17 | 9 | |
| Baseline VA | 0.480 (0.300, 0.651) | 0.602 (0.300, 1.088) | 0.903 (0.521, 1.626) | 0.1246* |
| 12-month VA | 0.200 (0.100, 0.449) | 0.200 (0.100, 1.000) | 0.480 (0.300, 1.577) | 0.1266* |
| 12-month change in VA | −0.300 (−0.439, 0.049) | −0.100 (−0.410, 0.300) | 0.000 (−0.400, 0.300) | 0.5780* |
| Baseline CSMT | 551 (407, 593) | 659 (421, 708) | 596 (414, 736) | 0.1901* |
| 12-month CSMT | 332 (231, 429) | 314 (251, 446) | 495 (330, 694) | 0.0931* |
| 12-month change in CSMT | −179 (−95, −272) | −280 (−61, −345) | −124 (194, −321) | 0.4822* |
| Prevalence of baseline RAPD (%) | 15.4 | 23.5 | 44.4 | 0.4096** |
| Incidence of ASNV over 12 months (%) | 15.4 | 17.6 | 8.9 | 0.9040** |
Notes: Entries are medians (interquartile range). Grades of ischemia are 1 (mild), 2 (moderate), and 3 (severe).
*
P-values reflect Kruskal–Wallis testing.
**
P-values reflect likelihood ratio testing.
Abbreviations: ASNV, anterior segment neovascularization; CSMT, central subfield mean thickness; N, number of patients; RAPD, relative afferent pupillary defect; VA, visual acuity.